Atea Pharmaceuticals Newsroom

Express News | Bradley L. Radoff and Michael Torok: Collectively Own About 3% of Outstanding Shares of Atea Pharmaceuticals

ReutersDec 18 17:29 ET

Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process

BusinesswireDec 18 17:05 ET

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

GlobeNewswireDec 16 05:00 ET

Morgan Stanley Maintains Atea Pharmaceuticals(AVIR.US) With Hold Rating, Maintains Target Price $6.2

Moomoo NewsDec 5 12:31 ET · Ratings

Atea Pharmaceuticals Hold Rating: Promising Phase 2 Outcomes Amidst Clinical and Market Challenges

TipRanksDec 5 12:18 ET · Ratings

After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study

BenzingaDec 4 15:14 ET

Express News | Atea Pharmaceuticals Inc: Global Phase 3 Program Initiation Expected Early in 2025

ReutersDec 4 08:20 ET

Express News | Atea Pharmaceuticals Announced That The Company's Phase 2 Study Of The Regimen Of Bemnifosbuvir, A Nucleotide Analog Polymerase Inhibitor, And Ruzasvir, An Ns5a Inhibitor, For Treatment Of Hepatitis C Virus Met Its Primary Endpoints Of Safety And...

BenzingaDec 4 07:02 ET

Express News | Atea Pharmaceuticals Inc - Phase 2 Study Achieves 98% Svr12 After 8 Weeks

ReutersDec 4 07:01 ET

Express News | Atea Pharmaceuticals Inc - No Drug-Related Serious Adverse Events or Treatment Discontinuations

ReutersDec 4 07:01 ET

Express News | Atea Pharmaceuticals Inc - Regimen Generally Safe and Well-Tolerated

ReutersDec 4 07:00 ET

Atea Pharmaceuticals Announces Positive Results From Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)

GlobeNewswireDec 4 07:00 ET

Express News | Atea Pharmaceuticals to Present and Provide a Business Update at the 7TH Annual Evercore Healthconx Conference

ReutersNov 26 07:00 ET

Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference

GlobeNewswireNov 26 07:00 ET

Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?

Yahoo FinanceNov 22 09:40 ET

Atea Pharmaceuticals Presents Three HCV Poster Presentations at AASLD

TipRanksNov 15 11:05 ET

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024

GlobeNewswireNov 15 11:00 ET

Express News | Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at Aasld’s the Liver Meeting 2024

ReutersNov 15 11:00 ET

Morgan Stanley Maintains Atea Pharmaceuticals(AVIR.US) With Hold Rating, Cuts Target Price to $6.2

Moomoo NewsNov 11 08:37 ET · Ratings

Atea Pharmaceuticals Advances in HCV Treatment Development

TipRanksNov 8 00:25 ET